Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Gyre Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +5 vs. Q4 2023
- Shares held
- 816.8K
- +210.0K (+34.6%) vs. Q4 2023
- Total value
- $14.3M
- −$1.32M (−8.5%) vs. Q4 2023
- New holders
- 10
- 6 more added
- Sold out
- 5
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GYRE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $57.1M |
| Q1 2026 | 56 | $23.8M |
| Q4 2025 | 44 | $23.6M |
| Q3 2025 | 48 | $23.1M |
| Q2 2025 | 48 | $25.1M |
| Q1 2025 | 46 | $20.1M |
| Q4 2024 | 41 | $21.6M |
| Q3 2024 | 37 | $20.2M |
| Q2 2024 | 30 | $15.0M |
| Q1 2024 | 21 | $14.3M |
| Q4 2023 | 16 | $15.6M |
| Q3 2023 | 32 | $1.04M |
| Q2 2023 | 29 | $796.3K |
| Q1 2023 | 40 | $707.6K |
| Q4 2022 | 35 | $2.63M |
| Q3 2022 | 35 | $3.90M |
| Q2 2022 | 41 | $14.2M |
| Q1 2022 | 43 | $6.39M |
| Q4 2021 | 51 | $13.7M |
| Q3 2021 | 66 | $75.7M |
| Q2 2021 | 69 | $87.7M |
| Q1 2021 | 89 | $113.0M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Gyre Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 195,098 | $3.41M | 0.00% | −2,999−1.5% | Reduced |
| BlackRock Inc. | 171,802 | $3.00M | 0.00% | −10,355−5.7% | Reduced |
| Geode Capital Management, LLC | 160,589 | $2.81M | 0.00% | +26,164+19.5% | Added |
| Millennium Management LLC | 60,319 | $1.05M | 0.00% | +60,319 | New |
| Goldman Sachs Group Inc | 46,093 | $805.7K | 0.00% | +46,093 | New |
| State Street Corp | 40,538 | $708.6K | 0.00% | +26,200+182.7% | Added |
| Jane Street Group, LLC | 30,555 | $534.1K | 0.00% | +30,555 | New |
| Marshall Wace, LLP | 25,544 | $446.5K | 0.00% | +25,544 | New |
| Northern Trust Corp | 24,068 | $420.7K | 0.00% | −546−2.2% | Reduced |
| JPMorgan Chase & Co | 20,028 | $350.1K | 0.00% | +19,736+6,758.9% | Added |
| Balyasny Asset Management LLC | 13,979 | $244.4K | 0.00% | +13,979 | New |
| Citigroup Inc | 12,168 | $212.7K | 0.00% | +4,420+57.0% | Added |
| Qube Research & Technologies Ltd | 6,235 | $109.0K | 0.00% | −510−7.6% | Reduced |
| Morgan Stanley | 5,706 | $99.7K | 0.00% | +5,706 | New |
| Tower Research Capital LLC (TRC) | 2,852 | $49.9K | 0.00% | +2,186+328.2% | Added |
| BNP Paribas Arbitrage, SA | 718 | $12.6K | 0.00% | +718 | New |
| Wells Fargo & Company | 96 | $1.68K | 0.00% | +2+2.1% | Added |
| Old Point Trust & Financial Services N A | 33 | $577 | 0.00% | +33 | New |
| Advisor Group Holdings, Inc. | 14 | $245 | 0.00% | 00.0% | Unchanged |
| Macquarie Group Ltd | 408 | $7 | 0.00% | +408 | New |
| Acadian Asset Management LLC | 1 | $0 | 0.00% | +1 | New |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −19,901−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −17,085−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −333−100.0% | Sold out |
| Wetzel Investment Advisors, Inc. | 0 | $0 | 0.00% | −266−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −66−100.0% | Sold out |